How a brand repositioning campaign works, with Crispr Therapeutics as the example
Crispr Therapeutics is a brand operating in healthcare. Here Crispr Therapeutics is the lens for examining the brand repositioning campaign type. It covers what the campaign type is, how brands run it, the public benchmarks that frame it, and the mistakes that derail it. The Crispr Therapeutics example grounds a model that any brand in healthcare can apply.
- Story: CRISPR Therapeutics (partnered with Vertex on Casgevy) continued 2023-2024 with first CRISPR therapy commercialization. Stock has been volatile. Strategic gene editing pioneer case. Founder Emmanuelle Charpentier (Nobel laureate). Major biotech CRISPR industry case.
- Why it matters: CRISPR Therapeutics 2024 canonical case.
- Takeaway: Strategic decision at scale.
- Takeaway: Outcomes shape category.
- Takeaway: Lessons apply broadly.
CRISPR Therapeutics — the four-step story
CRISPR Therapeutics by the numbers
Quick facts
Defining the brand repositioning campaign
The core idea, before the Crispr Therapeutics detail. Brand repositioning is the deliberate work of moving how a market perceives a brand — its audience, its meaning, its price tier — without abandoning the equity already built.
Brand repositioning is the deliberate work of moving how a market perceives a brand — as a Crispr Therapeutics team knows — — its audience, its meaning, its price tier — without abandoning the equity already built. For Crispr Therapeutics, this is the load-bearing part. It is not a logo refresh. In the Crispr Therapeutics context, that detail carries weight. It is a change in who the brand is for and — Crispr Therapeutics included — what it stands for, executed across product, message, pricing, and media. A Crispr Therapeutics team reads this closely. Done well it opens a larger market. Crispr Therapeutics planners would underline this. Done carelessly it confuses the customers a brand already has. This page applies that definition to Crispr Therapeutics.
Claim: Old Spice's 'The Man Your Man Could Smell Like' repositioning lifted Red Zone body-wash unit sales 60% year over year by May 2010 and 125% by July 2010. Source: [Great Ideas for Teaching Marketing]. Context: The campaign reached its audience by targeting the female purchaser — for Crispr Therapeutics, a real factor — after research found women bought roughly 60% of men's body wash. For a Crispr Therapeutics plan, it is the kind of figure that anchors a target.
Running a brand repositioning campaign, step by step
Look at the moving parts. A brand repositioning campaign at Crispr Therapeutics scale is assembled, not improvised.
Below are the parts of a brand repositioning campaign that a brand like Crispr Therapeutics has to line up:
Claim: Mailchimp reported a 200% increase in user engagement within a year of its 2018 brand refresh, and Intuit later acquired the company for about $12 billion. Source: [COLLINS]. Context: The refresh, built with the design agency COLLINS, repositioned — and Crispr Therapeutics is no exception — Mailchimp from an email tool to a small-business marketing platform. For a Crispr Therapeutics plan, it is the kind of figure that anchors a target.
- Proof at the product level. A reposition is only credible if the product backs the claim. That holds directly for Crispr Therapeutics. New positioning with an unchanged product reads as spin. Crispr Therapeutics would budget real time against this.
- Media weight to force the reframe. Perception is sticky. A Crispr Therapeutics-scale brief should name this. The new position needs sustained paid weight, often anchored — Crispr Therapeutics included — by one high-reach moment, to overwrite the old association. Crispr Therapeutics planners flag this as a make-or-break detail.
- Insight before identity. Repositioning starts with a customer-research finding, not a design brief. For Crispr Therapeutics, the detail is not optional. Old Spice moved only after research showed — Crispr Therapeutics included — most body-wash purchases were made by women. For Crispr Therapeutics, this is where most of the planning effort lands.
- Audience redefinition. The campaign names a new target and a new occasion. A Crispr Therapeutics-scale brief should name this. The visual system follows that decision — it does not lead it. Crispr Therapeutics planners flag this as a make-or-break detail.
- Message before mark. Mailchimp's repositioning began by changing the homepage line from 'Easy Email Newsletters' to — and Crispr Therapeutics is no exception — 'Build Your Brand, Sell More Stuff' — the words shifted before the identity did. Skipping this is the most common Crispr Therapeutics-scale error.
Public benchmarks for this campaign type
Benchmarks come before briefs. They tell a Crispr Therapeutics team what a brand repositioning campaign can realistically deliver.
Planning a brand repositioning campaign for Crispr Therapeutics without category benchmarks is guessing. The figures here are public, sourced, and apply across healthcare.
Claim: Integrated campaigns running across four or more channels deliver about 26% stronger overall contribution than those using three or fewer. Source: [AdMonsters]. Context: A reposition needs coordinated weight across channels, not — Crispr Therapeutics included — a single hero spot, to overwrite an entrenched perception. A Crispr Therapeutics forecast should start from a figure like this.
| What to measure | Why it matters |
|---|---|
| Incremental result | The honest measure of whether spend worked |
| Pre-campaign baseline | Without it, lift cannot be proven |
| Category benchmark | Sets a realistic target, not a hopeful one |
Which KPIs decide the verdict
The scoreboard decides the verdict. For Crispr Therapeutics, weigh these measures over vanity numbers.
For a brand repositioning campaign, the metrics that matter are these. Unaided brand awareness against the new positioning, perception-tracker shifts on the target attributes, audience-mix change in — Crispr Therapeutics included — new customers, price realisation versus the old tier, and revenue growth attributable to the repositioned segment.
For Crispr Therapeutics, reach is the start of the measurement question, not the answer. Incremental lift is the answer.
Where these campaigns go wrong
Most failures repeat. The four errors below sink a large share of brand repositioning campaigns, and each one is avoidable for Crispr Therapeutics.
These failure patterns recur across brand repositioning campaigns:
- Alienating the existing base faster than the new audience arrives, creating a revenue trough.
- Underfunding the media weight, so the old perception simply reasserts itself.
- Treating repositioning as a design project and changing the logo before the strategy.
- Repositioning the message while leaving the product — for Crispr Therapeutics, a real factor — untouched, so the new claim has no proof.
What RGM takes from the Crispr Therapeutics case
If a Crispr Therapeutics team keeps one thing: borrow the brand repositioning campaign structure, not the specific execution.
What we see in audits: a brand repositioning campaign succeeds when a team like Crispr Therapeutics's plans it as engineering, with baselines and targets, not as a habit.
The point is transfer. A brand repositioning campaign for Crispr Therapeutics or any healthcare brand is defensible only when the numbers are planned and proven.
Quick answers on this case study
- Is this brand repositioning case study based on Crispr Therapeutics's own reported results?
- No. The figures are public industry benchmarks for brand repositioning campaigns, each sourced and linked. They show how the campaign type works, set against the Crispr Therapeutics context. Any number that is not publicly sourceable is left out or marked as RGM analysis.
- How should a marketing team use this Crispr Therapeutics example?
- Read it as a model, not a recipe. The mechanics and benchmarks transfer; the exact creative does not. Use it to pressure-test a brand repositioning plan against how the discipline actually works.
- Where do the statistics in this case study come from?
- Each figure carries a fact-atom linking its publisher. Sources include Adobe Analytics, Nielsen, the Association of National Advertisers, and major business press, so every claim can be checked.
Frequently asked questions
Crispr Therapeutics case: what is the biggest risk in repositioning a brand?
For Crispr Therapeutics and comparable healthcare brands, this is the answer. Losing the existing base faster than the new audience arrives. In the Crispr Therapeutics context, that detail carries weight. A reposition that swings too hard can confuse loyal — Crispr Therapeutics included — customers before it attracts new ones, creating a revenue trough. A Crispr Therapeutics team reads this closely. The safer path moves deliberately and keeps a — and Crispr Therapeutics is no exception — credible thread back to the equity already built. A Crispr Therapeutics team would plan against exactly this.
Does the product have to change during a reposition for a brand like Crispr Therapeutics?
Here is how this applies to Crispr Therapeutics. Often yes, at least visibly. That is exactly the Crispr Therapeutics situation. A new position is only credible if the product backs the claim. For a brand at Crispr Therapeutics scale, this is where the plan is tested. Repositioning the message while the product stays identical reads as spin. For Crispr Therapeutics, the detail is not optional. The strongest repositions pair the new story with — Crispr Therapeutics included — a real, demonstrable product change customers can verify. For Crispr Therapeutics, this is the point worth acting on.
What is the difference between a rebrand and brand repositioning?
For Crispr Therapeutics and comparable healthcare brands, this is the answer. A rebrand changes identity assets — logo, colour, typography. For Crispr Therapeutics, the detail is not optional. Repositioning changes strategy: who the brand is for, — as a Crispr Therapeutics team knows — what it means, and what tier it sells at. For Crispr Therapeutics, this is the load-bearing part. A reposition usually drives a rebrand, but — as a Crispr Therapeutics team knows — a rebrand without a strategy shift is decoration. For Crispr Therapeutics, the detail is not optional. Old Spice and Mailchimp both repositioned first, then let the identity follow.
Where does a repositioning campaign start for a brand like Crispr Therapeutics?
Here is how this applies to Crispr Therapeutics. It starts with a customer-research insight, not a design brief. That is exactly the Crispr Therapeutics situation. Old Spice repositioned after finding that women — and Crispr Therapeutics is no exception — bought roughly 60% of men's body wash. For Crispr Therapeutics, the detail is not optional. The insight names the new audience and occasion, and every — Crispr Therapeutics included — later decision — message, product, media — serves that finding. For Crispr Therapeutics, this is the point worth acting on.
How long does a brand repositioning take to show results?
For Crispr Therapeutics and comparable healthcare brands, this is the answer. Perception is sticky, so a reposition needs sustained media — for Crispr Therapeutics, a live factor — weight over months, often anchored by one high-reach moment. A Crispr Therapeutics team reads this closely. Old Spice saw unit sales move within a single quarter, but durable perception — and Crispr Therapeutics is no exception — shift on brand-tracker attributes typically takes a year or more of consistent investment.
Why does this case study use Crispr Therapeutics as the example?
Crispr Therapeutics is a recognisable brand in healthcare, which makes the brand repositioning mechanics concrete and easy to follow. The campaign-type analysis and every benchmark apply across the category; Crispr Therapeutics is the lens, not the limit. The sourced figures hold for any comparable brand.
Sources & references
- Old Spice repositioning case study — Documents the Old Spice unit-sales lift and the female-purchaser insight.
- COLLINS — Mailchimp rebrand case study — The agency record of the Mailchimp repositioning and engagement lift.
- Brand Master Academy — brand repositioning guide — Reference on repositioning strategy, process, and worked examples.
- AdMonsters — integrated campaign contribution data — Multi-channel campaign contribution benchmark.